GLPwatch
Papers (10372)
Page 21 of 173, ranked by citation count.
- Glucagon-Like Peptide-1 Receptor Agonist Attenuates Autophagy to Ameliorate Pulmonary Arterial Hypertension through Drp1/NOX- and Atg-5/Atg-7/Beclin-1/LC3β Pathways.
- Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson's disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The 'Exenatide-PD3' study.
- Gut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutide.
- Protection of glucagon-like peptide-1 in cisplatin-induced renal injury elucidates gut-kidney connection.
- Injectable and Thermosensitive Hydrogel Containing Liraglutide as a Long-Acting Antidiabetic System.
- Liraglutide relieves myocardial damage by promoting autophagy via AMPK-mTOR signaling pathway in zucker diabetic fatty rat.
- Glucagon-like peptide-1 receptor action in the vasculature.
- Weight beneficial treatments for type 2 diabetes.
- Evolution of exenatide as a diabetes therapeutic.
- Glucagon-Like Peptide-1 Receptor Analogues in Type 2 Diabetes: Their Use and Differential Features.
- Comparison of triple quadrupole and high-resolution TOF-MS for quantification of peptides.
- Anti-inflammatory properties of antidiabetic drugs: A "promised land" in the COVID-19 era?
- Chemical Conjugation of Evans Blue Derivative: A Strategy to Develop Long-Acting Therapeutics through Albumin Binding.
- Psychological and quality of life changes in patients using GLP-1 analogues.
- Exenatide (a GLP-1 agonist) expresses anti-inflammatory properties in cultured human monocytes/macrophages in a protein kinase A and B/Akt manner.
- Transformation of oligomers of lipidated peptide induced by change in pH.
- Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors: a case/non-case study from the French Pharmacovigilance Database.
- Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes: Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6.
- Glucagon and heart in type 2 diabetes: new perspectives.
- The Novel Dual GLP-1/GIP Receptor Agonist DA-CH5 Is Superior to Single GLP-1 Receptor Agonists in the MPTP Model of Parkinson's Disease.
- Mechanisms of Action of Liraglutide in Patients With Type 2 Diabetes Treated With High-Dose Insulin.
- Semaglutide in Patients With Obesity and Heart Failure Across Mildly Reduced or Preserved Ejection Fraction.
- Glucagon-like peptide-1 receptor stimulation increases GFR and suppresses proximal reabsorption in the rat.
- Geniposide and its iridoid analogs exhibit antinociception by acting at the spinal GLP-1 receptors.
- Anorectic and aversive effects of GLP-1 receptor agonism are mediated by brainstem cholecystokinin neurons, and modulated by GIP receptor activation.
- Glucagon-like Peptide-1 receptor Tie2+ cells are essential for the cardioprotective actions of liraglutide in mice with experimental myocardial infarction.
- Umami receptor activation increases duodenal bicarbonate secretion via glucagon-like peptide-2 release in rats.
- Efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease.
- Exendin-4 improves β-cell function in autophagy-deficient β-cells.
- Exendin-4 Protects Against Myocardial Ischemia-Reperfusion Injury by Upregulation of SIRT1 and SIRT3 and Activation of AMPK.
- The effect of addition of liraglutide to high-dose intensive insulin therapy: a randomized prospective trial.
- Semaglutide-mediated protection against Aβ correlated with enhancement of autophagy and inhibition of apotosis.
- Exendin-4 protected against cognitive dysfunction in hyperglycemic mice receiving an intrahippocampal lipopolysaccharide injection.
- Anti-inflammatory role of DPP-4 inhibitors in a nondiabetic model of glomerular injury.
- Exendin-4 protects pancreatic beta cells from palmitate-induced apoptosis by interfering with GPR40 and the MKK4/7 stress kinase signalling pathway.
- Activation of glucagon-like peptide-1 receptor inhibits growth and promotes apoptosis of human pancreatic cancer cells in a cAMP-dependent manner.
- Semaglutide attenuates excessive exercise-induced myocardial injury through inhibiting oxidative stress and inflammation in rats.
- Involvement of cAMP/EPAC/TRPM2 activation in glucose- and incretin-induced insulin secretion.
- A 6-month randomized, double-blind, placebo-controlled trial of weekly exenatide in adolescents with obesity.
- Bone resorption is unchanged by liraglutide in type 2 diabetes patients: A randomised controlled trial.
- Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes.
- Semaglutide and cancer: A systematic review and meta-analysis.
- Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial.
- Effects of exenatide, insulin, and pioglitazone on liver fat content and body fat distributions in drug-naive subjects with type 2 diabetes.
- Chronic administration of the glucagon-like peptide-1 analog, liraglutide, delays the onset of diabetes and lowers triglycerides in UCD-T2DM rats.
- Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit*.
- Exenatide treatment for 6 months improves insulin sensitivity in adults with type 1 diabetes.
- Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): A randomized, open-label, multinational, phase 3b trial.
- Physiology and emerging biochemistry of the glucagon-like peptide-1 receptor.
- Effectiveness of semaglutide versus liraglutide for treating post-metabolic and bariatric surgery weight recurrence.
- Exendin-4 alleviates retinal vascular leakage by protecting the blood-retinal barrier and reducing retinal vascular permeability in diabetic Goto-Kakizaki rats.
- The effects of treatment with liraglutide on atherothrombotic risk in obese young women with polycystic ovary syndrome and controls.
- Liraglutide effects in a paediatric (7-11 y) population with obesity: A randomized, double-blind, placebo-controlled, short-term trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics.
- Exendin-4 attenuates renal tubular injury by decreasing oxidative stress and inflammation in streptozotocin-induced diabetic mice.
- Exenatide once weekly slows gastric emptying of solids and liquids in healthy, overweight people at steady-state concentrations.
- Separate and combined effects of semaglutide and empagliflozin on kidney oxygenation and perfusion in people with type 2 diabetes: a randomised trial.
- GLP-1 receptor agonists for weight reduction in people living with obesity but without diabetes: a living benefit-harm modelling study.
- Medication adherence to injectable glucagon-like peptide-1 (GLP-1) receptor agonists dosed once weekly vs once daily in patients with type 2 diabetes: A meta-analysis.
- Effect of dulaglutide in promoting abstinence during smoking cessation: a single-centre, randomized, double-blind, placebo-controlled, parallel group trial.
- Exendin-4 attenuates adverse cardiac remodelling in streptozocin-induced diabetes via specific actions on infiltrating macrophages.